Pfizer (PFE)
(Real Time Quote from BATS)
$28.00 USD
+0.30 (1.08%)
Updated Jul 5, 2024 02:58 PM ET
3-Hold of 5 3
B Value F Growth D Momentum D VGM
Brokerage Reports
Pfizer Inc. [PFE]
Reports for Purchase
Showing records 541 - 560 ( 565 total )
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
MODEL STOCK PORTFOLIO -CONSERVATIVE GROWTH
Provider: J.J.B. Hilliard, W.L. Lyons
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
First Quarter 2011 Revenue About Even. Non-GAAP EPS Exceeded Consensus Expectations.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Despite Headwinds in the U.S. and Europe, Fourth Quarter Revenue Exceeded Expectations
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Management raises guidance for CY10 & maintains earlier guidance for CY12....
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Several Factors Held Back Third Quarter Revenue
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S